• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Inhibitory effects of antiparasitic drugs on cytochrome P450 2D6.

作者信息

Masimirembwa C M, Hasler J A, Johansson I

机构信息

Department of Biochemistry, University of Zimbabwe, Mt Pleasant, Harare.

出版信息

Eur J Clin Pharmacol. 1995;48(1):35-8. doi: 10.1007/BF00202169.

DOI:10.1007/BF00202169
PMID:7621845
Abstract

The interaction of antiparasitic drugs with the polymorphic cytochrome P450 2D6 was studied in human liver microsomes. Of ten different drugs tested, three quinolines, oxamniquine, primaquine and chloroquine inhibited microsomal CYP2D6-catalysed formation of 1'hydroxybufuralol at concentrations that might have clinical consequences in drug use. These drugs inhibited competitively bufuralol metabolism with Ki values of 22, 23 and 15 microM, respectively, indicative of high affinity for the CYP2D6-active site. The results imply that oxamniquine, primaquine and chloroquine could be substrates of cytochrome P4502 D6 or that they are potent non-substrate inhibitors of the enzyme similar to quinidine. In either case, the inhibition of CYP2D6 by these agents could lead to interference with in vivo population-phenotyping procedures in the tropical regions where treatment with the drugs is common.

摘要

相似文献

1
Inhibitory effects of antiparasitic drugs on cytochrome P450 2D6.
Eur J Clin Pharmacol. 1995;48(1):35-8. doi: 10.1007/BF00202169.
2
Bufuralol hydroxylation by cytochrome P450 2D6 and 1A2 enzymes in human liver microsomes.人肝微粒体中细胞色素P450 2D6和1A2酶对布呋洛尔的羟基化作用。
Mol Pharmacol. 1994 Sep;46(3):568-77.
3
The role of CYP2C19 in the metabolism of (+/-) bufuralol, the prototypic substrate of CYP2D6.细胞色素P450 2C19（CYP2C19）在（±）布库洛尔（CYP2D6的原型底物）代谢中的作用。
Drug Metab Dispos. 1999 Sep;27(9):1024-8.
4
(+)-bufuralol 1'-hydroxylation activity in human and rhesus monkey intestine and liver.人及恒河猴肠道和肝脏中（+）-布呋洛尔1'-羟化活性
Biochem Pharmacol. 1995 Oct 26;50(9):1521-5. doi: 10.1016/0006-2952(95)02052-7.
5
Timolol metabolism in human liver microsomes is mediated principally by CYP2D6.噻吗洛尔在人肝微粒体中的代谢主要由CYP2D6介导。
Drug Metab Dispos. 2007 Jul;35(7):1135-41. doi: 10.1124/dmd.106.012906. Epub 2007 Apr 12.
6
An investigation of the interaction between halofantrine, CYP2D6 and CYP3A4: studies with human liver microsomes and heterologous enzyme expression systems.卤泛群、CYP2D6和CYP3A4之间相互作用的研究：用人肝微粒体和异源酶表达系统进行的研究。
Br J Clin Pharmacol. 1995 Oct;40(4):369-78. doi: 10.1111/j.1365-2125.1995.tb04559.x.
7
The polymorphic cytochrome P-4502D6 is involved in the metabolism of both 5-hydroxytryptamine antagonists, tropisetron and ondansetron.多态性细胞色素P-4502D6参与5-羟色胺拮抗剂托烷司琼和昂丹司琼的代谢。
Drug Metab Dispos. 1994 Mar-Apr;22(2):269-74.
8
A monoclonal antibody inhibitory to human P450 2D6: a paradigm for use in combinatorial determination of individual P450 role in specific drug tissue metabolism.一种抑制人细胞色素P450 2D6的单克隆抗体：用于组合测定个体P450在特定药物组织代谢中作用的范例。
Pharmacogenetics. 1997 Dec;7(6):469-77. doi: 10.1097/00008571-199712000-00005.
9
Identification of human liver cytochrome P450 enzymes that metabolize the nonsedating antihistamine loratadine. Formation of descarboethoxyloratadine by CYP3A4 and CYP2D6.鉴定参与代谢非镇静性抗组胺药氯雷他定的人肝脏细胞色素P450酶。CYP3A4和CYP2D6介导形成去乙氧羰基氯雷他定。
Biochem Pharmacol. 1996 Jan 26;51(2):165-72. doi: 10.1016/0006-2952(95)02169-8.
10
Development of a pharmacophore for inhibition of human liver cytochrome P-450 2D6: molecular modeling and inhibition studies.用于抑制人肝细胞色素P-450 2D6的药效团的开发：分子建模与抑制研究
J Med Chem. 1993 Apr 30;36(9):1136-45. doi: 10.1021/jm00061a004.

引用本文的文献

1
Will the Use of Pharmacogenetics Improve Treatment Efficiency in COVID-19?药物遗传学的应用能否提高新冠病毒肺炎的治疗效率？
Pharmaceuticals (Basel). 2022 Jun 13;15(6):739. doi: 10.3390/ph15060739.
2
Pharmacogenomics and COVID-19: clinical implications of human genome interactions with repurposed drugs.药物基因组学与 COVID-19：人类基因组与再利用药物相互作用的临床意义。
Pharmacogenomics J. 2021 Jun;21(3):275-284. doi: 10.1038/s41397-021-00209-9. Epub 2021 Feb 4.
3
Metabolism and Interactions of Chloroquine and Hydroxychloroquine with Human Cytochrome P450 Enzymes and Drug Transporters.

本文引用的文献

1
Development of a pharmacophore for inhibition of human liver cytochrome P-450 2D6: molecular modeling and inhibition studies.用于抑制人肝细胞色素P-450 2D6的药效团的开发：分子建模与抑制研究
J Med Chem. 1993 Apr 30;36(9):1136-45. doi: 10.1021/jm00061a004.
2
Cytochromes P450: their active-site structure and mechanism of oxidation.细胞色素P450：其活性位点结构与氧化机制
Drug Metab Rev. 1993;25(3):325-87. doi: 10.3109/03602539308993979.
3
Metabolic polymorphisms.代谢多态性
氯喹和羟氯喹与人细胞色素 P450 酶和药物转运体的代谢和相互作用。
Curr Drug Metab. 2020;21(14):1127-1135. doi: 10.2174/1389200221999201208211537.
4
[Not Available].[无可用内容]。
CMAJ. 2020 Oct 13;192(41):E1242-E1246. doi: 10.1503/cmaj.200528-f.
5
Psychiatric Aspects of Chloroquine and Hydroxychloroquine Treatment in the Wake of Coronavirus Disease-2019: Psychopharmacological Interactions and Neuropsychiatric Sequelae.新型冠状病毒病 2019 后氯喹和羟氯喹治疗的精神科方面：精神药理学相互作用和神经精神后遗症。
Psychosomatics. 2020 Nov-Dec;61(6):597-606. doi: 10.1016/j.psym.2020.06.022. Epub 2020 Jul 8.
6
Safety considerations with chloroquine, hydroxychloroquine and azithromycin in the management of SARS-CoV-2 infection.氯喹、羟氯喹和阿奇霉素用于治疗新型冠状病毒肺炎（SARS-CoV-2感染）时的安全性考量
CMAJ. 2020 Apr 27;192(17):E450-E453. doi: 10.1503/cmaj.200528. Epub 2020 Apr 8.
7
Are circulating metabolites important in drug-drug interactions?: Quantitative analysis of risk prediction and inhibitory potency.循环代谢物在药物相互作用中重要吗？：风险预测和抑制效力的定量分析。
Clin Pharmacol Ther. 2011 Jan;89(1):105-13. doi: 10.1038/clpt.2010.252. Epub 2010 Dec 1.
8
Spectrofluorimetric determination of oxamniquine in dosage forms and spiked human plasma through derivatization with 1-dimethylaminonaphthalene-5-sulphonyl chloride.通过与1-二甲基氨基萘-5-磺酰氯衍生化，用荧光分光光度法测定剂型和加标人血浆中的奥沙尼喹。
J Fluoresc. 2008 Mar;18(2):349-55. doi: 10.1007/s10895-007-0274-1. Epub 2007 Dec 5.
9
Computational models to assign biopharmaceutics drug disposition classification from molecular structure.基于分子结构进行生物药剂学药物处置分类的计算模型。
Pharm Res. 2007 Dec;24(12):2249-62. doi: 10.1007/s11095-007-9435-9. Epub 2007 Sep 11.
10
The role of CYP2C and CYP3A in the disposition of 3-keto-desogestrel after administration of desogestrel.炔诺酮给药后CYP2C和CYP3A在3-酮-去氧孕烯处置中的作用。
Br J Clin Pharmacol. 2005 Jul;60(1):69-75. doi: 10.1111/j.1365-2125.2005.02382.x.
Pharmacol Ther. 1993 Feb-Mar;57(2-3):129-60. doi: 10.1016/0163-7258(93)90053-g.
4
Drug metabolism in human liver in vitro: establishment of a human liver bank.人肝脏体外药物代谢：人肝脏库的建立
Clin Pharmacol Ther. 1980 Jun;27(6):711-25. doi: 10.1038/clpt.1980.102.
5
Pharmacologic actions of 4-aminoquinoline compounds.4-氨基喹啉化合物的药理作用。
Am J Med. 1983 Jul 18;75(1A):5-10. doi: 10.1016/0002-9343(83)91264-0.
6
Substrate specificity of human liver cytochrome P-450 debrisoquine 4-hydroxylase probed using immunochemical inhibition and chemical modeling.利用免疫化学抑制和化学建模探究人肝细胞色素P-450异喹胍4-羟化酶的底物特异性。
Cancer Res. 1985 May;45(5):2116-22.
7
Clinical pharmacokinetics of antimalarial drugs.抗疟药物的临床药代动力学。
Clin Pharmacokinet. 1985 May-Jun;10(3):187-215. doi: 10.2165/00003088-198510030-00001.
8
Pharmacokinetics and metabolism of quinidine in extensive and poor metabolisers of sparteine.
Eur J Clin Pharmacol. 1986;31(1):69-72. doi: 10.1007/BF00870989.
9
High-performance liquid chromatographic assays for bufuralol 1'-hydroxylase, debrisoquine 4-hydroxylase, and dextromethorphan O-demethylase in microsomes and purified cytochrome P-450 isozymes of human liver.人肝微粒体及纯化的细胞色素P-450同工酶中布呋洛尔1'-羟化酶、异喹胍4-羟化酶和右美沙芬O-脱甲基酶的高效液相色谱测定法
Anal Biochem. 1987 Apr;162(1):24-32. doi: 10.1016/0003-2697(87)90006-6.
10
Mechanisms of the inhibition of cytochrome P-450-mediated drug oxidation by therapeutic agents.治疗药物对细胞色素P-450介导的药物氧化的抑制机制。
Drug Metab Rev. 1987;18(1):55-81. doi: 10.3109/03602538708998300.